PHA-793887 is a popular compound with its CAS number being 718630-59-2. It is a small molecule inhibitor in the drug class of cyclin-dependent kinase (CDK) which is being used widely for research and potential medical purposes.
Chemical name - PHA-793887 Molecular formula - C17H18N4O2S Formula weight - 342.42 g/mol CAS No - 718630-59-2
Top ten keywords from Google and Synonyms:
Health benefits of this product: Studies depict that PHA-793887 is helpful in the treatment of cancer and neurological disorders. Specifically, this drug is known for its cell cycle regulation properties, which in turn aids in controlling and preventing the proliferation of cancer cells. Therefore, PHA-793887 has become a promising anti-cancer agent, providing hope to many individuals suffering from various types of tumors.
Potential effects: PHA-793887 has been found to have potential effects on cell proliferation regulation. Research shows that PHA-793887 can inhibit the growth of different types of cancer cells, such as lung cancer, breast cancer, and colon cancer. Studies have also shown that PHA-793887 is effective in controlling the growth of cancer cells that are resistant to traditional chemotherapy treatments. Furthermore, it has been observed that PHA-793887 can fight some neurological disorders, including Alzheimer's disease, Parkinson's disease, and stroke.
Product mechanism: PHA-793887, being a small molecule inhibitor, functions by binding to CDK, which are crucial enzymes that regulate the cell cycle. By binding, it inhibits the proliferation of cancer cells, tumorigenesis, and tumor angiogenesis. Furthermore, PHA-793887 causes cell death by blocking the progression of the cell cycle without interfering with DNA synthesis.
Safety: Clinical studies have shown that PHA-793887 used in low doses, carefully administered, has a good safety profile. However, this drug should not be used by pregnant women or during breastfeeding without consulting a physician. Also, individuals who are allergic to sulfur-containing drugs should avoid using PHA-793887. Side effects of this drug may include weakness, fatigue, abdominal pain, and anemia.
Side effects: The following are some side effects reported for PHA-793887:
Dosing information: The dosing information for PHA-793887 is not yet definitively established. Much of the research to date has been conducted on mice, and it has yet to be established as safe and effective in humans for clinical use.
Conclusion: PHA-793887, as a CDK inhibitor, represents a promising therapy for different types of cancers and neurological disorders. It is effective in halting tumor development and fighting against drug-resistant cancer cells. Many preclinical studies show that it has the potential to become an effective anti-tumor drug in the future. However, while it seems to offer a lot of promise, further research is needed to establish its safety profile comprehensively and build the perfect dosing for effective therapy
